Stock AnalizCME Group Inc. CME
Investment Bankers/Brokers/Service · IPO 2002 · data as of November 13, 2026
CME Group Inc. (CME) is a financial company listed in the US with a market value of about $113.8B. In the twelve months to September 30, 2026 it had revenue of $7.0B and net income of $4.4B, a net margin of 63.3%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 26.1, a price to free cash flow of 26.3, 5-year revenue growth of 6% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 41% below the current price.
Score: 2.4 / 5
Checks passed
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0B | $6.5B | $6.1B | $5.6B | $5.0B | $4.7B | $4.9B | $4.9B | $4.3B | $3.6B | $3.6B |
| Net income | $4.4B | $4.1B | $3.5B | $3.2B | $2.7B | $2.6B | $2.1B | $2.1B | $2.0B | $4.1B | $1.5B |
| Free cash flow | $4.3B | $4.2B | $3.6B | $3.4B | $3.0B | $2.3B | $2.5B | $2.4B | $2.3B | $1.7B | $1.6B |
| EPS (diluted) | $12.19 | $11.16 | $9.67 | $8.86 | $7.40 | $7.29 | $5.87 | $5.91 | $5.71 | $11.94 | $4.53 |
| Net margin | 63.3% | 62.5% | 57.5% | 57.8% | 53.6% | 56.2% | 43.1% | 43.5% | 45.5% | 111.5% | 42.7% |
| ROIC | — | 10.1% | 10.2% | 8.8% | 7.7% | 6.7% | 6.9% | 6.7% | 6.1% | 7.4% | 6.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $317.06, 0% below the current price; targets range from $227.00 to $367.00; the consensus rating is “Buy”; expected EPS is $12.40 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is CME Group’s P/E ratio?
About 26.1, based on the last twelve months of diluted earnings per share (forward P/E about 24.5).
Is CME Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 41% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does CME Group pay a dividend?
Yes. The dividend yield is about 1.65%, and it has paid dividends for 10 years in our data.
Is CME Group a good stock to buy?
We do not give buy or sell advice. CME Group scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.